Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies

[#item_full_content]SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #BreastCancerResearch–Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced the successful closing of a $90 million Series D financing round, which includes the conversion of a convertible note. The financing was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital. The proceeds from the